therapeutic effectiveness of Siddha formulation Thanneervittan Nei in the management of Moothirakiricharam (Urinary Tract Infection) â?? A Pilot study

Scientific Validation on therapeutic effectiveness of Siddha formulation Thanneervittan Nei in the management of Moothirakiricharam (Urinary Tract Infection) â?? A Pilot study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/040777

Enrollment

Registered

2022-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Thannervittan nei: Drug: Thanneervittan Nei Dosage: 2 Thekkarandigal(10 gm) two times a day after food. Duration: 21 days Reference: Agathiyar1500 Control Intervention1: not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Positive urine culture test with or without clinical symptoms of UTI like painful micturition discoloration of urine burning micturition Ability to provide informed consent (or assent if under the age of 18) Willing for blood and urine investigation before and after treatment Willing to attend OPD or admission in IPD for 21 days

Exclusion criteria

Exclusion criteria: Known C/O Renal failure, Renal transplantation, Hepatic disease, Cancerous conditions Any other serious illness Known C/O Urinary Obstruction/ Stricture urethra Known C/O Dominant Polycystic Kidney Disease

Design outcomes

Primary

Measure	Time frame
The outcome of this study is the reduction of clinical symptomsTimepoint: 21 days	—

Secondary

Measure	Time frame
the secondary outcome is negative urine culture testTimepoint: 21 days	—

Countries

India

Contacts

Public ContactDr P M Indhu

National institute of siddha

ssknis@gmail.com9962528338

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026